Immunogenicity and Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children.
Phase of Trial: Phase III
Latest Information Update: 02 Nov 2016
At a glance
- Drugs GSK 1536489A; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 10 Feb 2012 Results published in the Pediatric Infectious Disease Journal.
- 10 Feb 2012 Primary endpoint 'Seroconversion-rate' has been met.
- 10 Feb 2012 Primary endpoint 'Geometric-mean-antibody-titre' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History